Gain Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
GT-02287, an AI-discovered GCase modulator, has shown safety, biomarker-driven efficacy, and stabilization of Parkinson's symptoms in early trials. Phase II is set for next quarter, with a focus on clinical and biomarker endpoints, and the company is exploring financing and partnership options.
-
A novel approach to Parkinson's targets disease biology by stabilizing GCase, with early clinical data showing safety, biomarker engagement, and stable motor scores. Phase II trials will stratify patients by biomarkers and begin in Q3, with further pipeline candidates in development.
-
A phase 1b study of GT-02287 in Parkinson's patients showed a 2.2-point improvement in MDS-UPDRS scores over 90 days, with strong biomarker evidence of reduced CSF glucosylsphingosine, indicating target engagement and potential disease-modifying effects. Final results and phase II initiation are expected later this year.
Fiscal Year 2025
-
A phase I-B study of GT-02287 in Parkinson's disease shows favorable safety and early signs of clinical improvement, with most adverse events mild and a majority of patients entering a nine-month extension. Biomarker and full clinical data are expected by year-end, with a phase II trial planned for next year.
Fiscal Year 2024
-
GT-02287, a GCase modulator, is advancing to Phase 1b trials in both GBA1 and idiopathic Parkinson's patients after promising human and preclinical data. The drug aims to modify disease progression by targeting cellular mechanisms, with initial results expected in the first half of next year.
-
Leadership transitioned to an interim CEO and executive chairman, with no change in strategy. Recent $11 million financing supports ongoing clinical development of GT-02287 for Parkinson's disease, with key trial results and a Phase 1b study upcoming.